Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 study of EDG-5506

Next Previous
Trial Profile

Phase 3 study of EDG-5506

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sevasemten (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 02 Apr 2025 According to a Edgewise Therapeutics media release, the company has announced the pricing of its 9,935,419 shares and anticipates gross proceeds from the offering to be approximately $200 million. The company intends to use the net proceeds from this offering to support many research activities along with the advancement of this trial.
  • 08 Aug 2024 According to a Edgewise Therapeutics media release, this trial is planned to be initiated in the first half of 2025.
  • 26 Oct 2023 According to a Edgewise Therapeutics media release, this trial is expected to start in the second half of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top